Publications | PubMed=4412247; DOI=10.1093/jnci/53.3.661; PMCID=PMC7364228 Cailleau R.M., Young R., Olive M., Reeves W.J. Jr. Breast tumor cell lines from pleural effusions. J. Natl. Cancer Inst. 53:661-674(1974) PubMed=1000504 Lippman M.E., Bolan G., Huff K. The effects of estrogens and antiestrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 36:4595-4601(1976) PubMed=1000505 Lippman M.E., Bolan G., Huff K. The effects of glucocorticoids and progesterone on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 36:4602-4609(1976) PubMed=1000506 Lippman M.E., Bolan G., Huff K. The effects of androgens and antiandrogens on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res. 36:4610-4618(1976) PubMed=833871; DOI=10.1093/jnci/58.2.209 Fogh J., Wright W.C., Loveless J.D. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58:209-214(1977) PubMed=77569; DOI=10.1111/j.1399-0039.1978.tb01259.x Espmark J.A., Ahlqvist-Roth L., Sarne L., Persson A. Tissue typing of cells in culture. III. HLA antigens of established human cell lines. Attempts at typing by the mixed hemadsorption technique. Tissue Antigens 11:279-286(1978) PubMed=730202; DOI=10.1007/BF02616120 Cailleau R.M., Olive M., Cruciger Q.V.J. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 14:911-915(1978) PubMed=7000337 Brinkley B.R., Beall P.T., Wible L.J., Mace M.L. Jr., Turner D.S., Cailleau R.M. Variations in cell form and cytoskeleton in human breast carcinoma cells in vitro. Cancer Res. 40:3118-3129(1980) PubMed=6935474; DOI=10.1093/jnci/66.2.239 Wright W.C., Daniels W.P., Fogh J. Distinction of seventy-one cultured human tumor cell lines by polymorphic enzyme analysis. J. Natl. Cancer Inst. 66:239-247(1981) PubMed=7272986; DOI=10.1016/0165-4608(81)90057-1 Satya-Prakash K.L., Pathak S., Hsu T.-C., Olive M., Cailleau R.M. Cytogenetic analysis on eight human breast tumor cell lines: high frequencies of 1q, 11q and HeLa-like marker chromosomes. Cancer Genet. Cytogenet. 3:61-73(1981) PubMed=7459858 Rousset M., Zweibaum A., Fogh J. Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins. Cancer Res. 41:1165-1170(1981) PubMed=6582512; DOI=10.1073/pnas.81.2.568; PMCID=PMC344720 Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O. Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984) PubMed=3518877; DOI=10.3109/07357908609038260 Fogh J. Human tumor lines for cancer research. Cancer Invest. 4:157-184(1986) PubMed=3335022 Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbott B.J., Mayo J.G., Shoemaker R.H., Boyd M.R. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res. 48:589-601(1988) PubMed=1961733; DOI=10.1073/pnas.88.23.10657; PMCID=PMC52989 Runnebaum I.B., Nagarajan M., Bowman M., Soto D., Sukumar S. Mutations in p53 as potential molecular markers for human breast cancer. Proc. Natl. Acad. Sci. U.S.A. 88:10657-10661(1991) PubMed=7902062 de la Torre M., Hao X.-Y., Larsson R., Nygren P., Tsuruo T., Mannervik B., Bergh J. Characterization of four doxorubicin adapted human breast cancer cell lines with respect to chemotherapeutic drug sensitivity, drug resistance associated membrane proteins and glutathione transferases. Anticancer Res. 13:1425-1430(1993) DOI=10.1016/B978-0-12-333530-2.50009-5 Leibovitz A. Cell lines from human breast. (In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York; USA (1994) PubMed=8824553; DOI=10.1002/(SICI)1097-0215(19960917)67:6<816::AID-IJC10>3.0.CO;2-# Mullen P., Ritchie A., Langdon S.P., Miller W.R. Effect of Matrigel on the tumorigenicity of human breast and ovarian carcinoma cell lines. Int. J. Cancer 67:816-820(1996) PubMed=9815641 Wosikowski K., Schuurhuis D.H., Kops G.J.P.L., Saceda M., Bates S.E. Altered gene expression in drug-resistant human breast cancer cells. Clin. Cancer Res. 3:2405-2414(1997) PubMed=9670966; DOI=10.4049/jimmunol.161.2.877 Bettinotti M.P., Kim C.J., Lee K.-H., Roden M., Cormier J.N., Panelli M.C., Parker K.K., Marincola F.M. Stringent allele/epitope requirements for MART-1/Melan A immunodominance: implications for peptide-based immunotherapy. J. Immunol. 161:877-889(1998) PubMed=9671407; DOI=10.1038/sj.onc.1201814 Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A. Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells. Oncogene 16:2865-2878(1998) PubMed=10700174; DOI=10.1038/73432 Ross D.T., Scherf U., Eisen M.B., Perou C.M., Rees C., Spellman P.T., Iyer V.R., Jeffrey S.S., van de Rijn M., Waltham M.C., Pergamenschikov A., Lee J.C.F., Lashkari D., Shalon D., Myers T.G., Weinstein J.N., Botstein D., Brown P.O. Systematic variation in gene expression patterns in human cancer cell lines. Nat. Genet. 24:227-235(2000) PubMed=10969801 Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y., Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P. Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data. Cancer Res. 60:4519-4525(2000) PubMed=11499871; DOI=10.1359/jbmr.2001.16.8.1486 Yoneda T., Williams P.J., Hiraga T., Niewolna M., Nishimura R. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro. J. Bone Miner. Res. 16:1486-1495(2001) PubMed=11687795; DOI=10.1038/ng754 Snijders A.M., Nowak N.J., Segraves R., Blackwood S., Brown N., Conroy J., Hamilton G., Hindle A.K., Huey B., Kimura K., Law S., Myambo K., Palmer J., Ylstra B., Yue J.P., Gray J.W., Jain A.N., Pinkel D., Albertson D.G. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat. Genet. 29:263-264(2001) PubMed=11697798; DOI=10.1359/jbmr.2001.16.11.2027 Peyruchaud O., Winding B., Pecheur I., Serre C.-M., Delmas P., Clezardin P. Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. J. Bone Miner. Res. 16:2027-2034(2001) PubMed=12068308; DOI=10.1038/nature00766 Davies H.R., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S., Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S., Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J., Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A., Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T., Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R., Marshall C.J., Wooster R., Stratton M.R., Futreal P.A. Mutations of the BRAF gene in human cancer. Nature 417:949-954(2002) PubMed=12353263; DOI=10.1002/gcc.10107 Popovici C., Basset C., Bertucci F., Orsetti B., Adelaide J., Mozziconacci M.-J., Conte N., Murati A., Ginestier C., Charafe-Jauffret E., Ethier S.P., Lafage-Pochitaloff M., Theillet C., Birnbaum D., Chaffanet M. Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene. Genes Chromosomes Cancer 35:204-218(2002) PubMed=12661003; DOI=10.1002/gcc.10196 Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U., Santibanez-Koref M.F., Schlag P.M., Scherneck S. Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines. Genes Chromosomes Cancer 37:29-35(2003) PubMed=12800145; DOI=10.1002/gcc.10218 Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M. A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene. Genes Chromosomes Cancer 37:333-345(2003) PubMed=15153330; DOI=10.1593/neo.3292; PMCID=PMC1502105 Watts G.S., Oshiro M.M., Junk D.J., Wozniak R.J., Watterson S.J., Domann F.E., Futscher B.W. The acetyltransferase p300/CBP-associated factor is a p53 target gene in breast tumor cells. Neoplasia 6:187-194(2004) PubMed=15677628; DOI=10.1093/carcin/bgi032 Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C. Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer. Carcinogenesis 26:923-930(2005) PubMed=15748285; DOI=10.1186/1479-5876-3-11; PMCID=PMC555742 Adams S., Robbins F.-M., Chen D., Wagage D., Holbeck S.L., Morse H.C. 3rd, Stroncek D., Marincola F.M. HLA class I and II genotype of the NCI-60 cell lines. J. Transl. Med. 3:11.1-11.8(2005) PubMed=15767549; DOI=10.1158/1535-7163.MCT-04-0234 Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., Yamori T. Chemosensitivity profile of cancer cell lines and identification of genes determining chemosensitivity by an integrated bioinformatical approach using cDNA arrays. Mol. Cancer Ther. 4:399-412(2005) PubMed=15900046; DOI=10.1093/jnci/dji133 Mashima T., Oh-hara T., Sato S., Mochizuki M., Sugimoto Y., Yamazaki K., Hamada J.-i., Tada M., Moriuchi T., Ishikawa Y., Kato Y., Tomoda H., Yamori T., Tsuruo T. p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target. J. Natl. Cancer Inst. 97:765-777(2005) PubMed=16049480; DOI=10.1038/nature03799; PMCID=PMC1283098 Minn A.J., Gupta G.P., Siegel P.M., Bos P.D., Shu W.-P., Giri D.D., Viale A.J., Olshen A.B., Gerald W.L., Massague J. Genes that mediate breast cancer metastasis to lung. Nature 436:518-524(2005) PubMed=16142302; DOI=10.3892/ijo.27.4.881 de Longueville F., Lacroix M., Barbuto A.-M., Bertholet V., Gallo D., Larsimont D., Marcq L., Zammatteo N., Boffe S., Leclercq G., Remacle J. Molecular characterization of breast cancer cell lines by a low-density microarray. Int. J. Oncol. 27:881-892(2005) PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853 Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M. BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants. Cancer Res. 66:41-45(2006) PubMed=16417655; DOI=10.1186/bcr1370; PMCID=PMC1413994 Shadeo A., Lam W.L. Comprehensive copy number profiles of breast cancer cell model genomes. Breast Cancer Res. 8:R9.1-R9.14(2006) PubMed=16541312; DOI=10.1007/s10549-006-9186-z Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M. Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines. Breast Cancer Res. Treat. 99:97-101(2006) PubMed=17088437; DOI=10.1158/1535-7163.MCT-06-0433; PMCID=PMC2705832 Ikediobi O.N., Davies H.R., Bignell G.R., Edkins S., Stevens C., O'Meara S., Santarius T., Avis T., Barthorpe S., Brackenbury L., Buck G., Butler A.P., Clements J., Cole J., Dicks E., Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J., Hunter C., Jenkinson A., Jones D., Kosmidou V., Lugg R., Menzies A., Mironenko T., Parker A., Perry J., Raine K.M., Richardson D., Shepherd R., Small A., Smith R., Solomon H., Stephens P.J., Teague J.W., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A., Reinhold W.C., Weinstein J.N., Stratton M.R., Futreal P.A., Wooster R. Mutation analysis of 24 known cancer genes in the NCI-60 cell line set. Mol. Cancer Ther. 5:2606-2612(2006) PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008; PMCID=PMC2730521 Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10:515-527(2006) PubMed=17334996; DOI=10.1002/gcc.20438 Jonsson G., Staaf J., Olsson E., Heidenblad M., Vallon-Christersson J., Osoegawa K., de Jong P.J., Oredsson S.M., Ringner M., Hoglund M., Borg A. High-resolution genomic profiles of breast cancer cell lines assessed by tiling BAC array comparative genomic hybridization. Genes Chromosomes Cancer 46:543-558(2007) PubMed=18516279; DOI=10.1016/j.molonc.2007.02.004; PMCID=PMC2391005 Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R., Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H., Petersen O.W., Gray J.W., Bissell M.J. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol. Oncol. 1:84-96(2007) PubMed=18277095; DOI=10.4161/cbt.7.5.5712 Berglind H., Pawitan Y., Kato S., Ishioka C., Soussi T. Analysis of p53 mutation status in human cancer cell lines: a paradigm for cell line cross-contamination. Cancer Biol. Ther. 7:699-708(2008) PubMed=18386134; DOI=10.1007/s10585-008-9169-z Hughes L., Malone C., Chumsri S., Burger A.M., McDonnell S. Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity. Clin. Exp. Metastasis 25:549-557(2008) PubMed=18714363; DOI=10.1593/neo.08570; PMCID=PMC2517647 Kischel P., Guillonneau F., Dumont B., Bellahcene A., Stresing V., Clezardin P., De Pauw E.A., Castronovo V. Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells. Neoplasia 10:1014-1020(2008) PubMed=19372543; DOI=10.1158/1535-7163.MCT-08-0921; PMCID=PMC4020356 Lorenzi P.L., Reinhold W.C., Varma S., Hutchinson A.A., Pommier Y., Chanock S.J., Weinstein J.N. DNA fingerprinting of the NCI-60 cell line panel. Mol. Cancer Ther. 8:713-724(2009) PubMed=19582160; DOI=10.1371/journal.pone.0006146; PMCID=PMC2702084 Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D., Pollack J.R. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS ONE 4:E6146-E6146(2009) DOI=10.25904/1912/1434 Morrison B.J. Breast cancer stem cells: tumourspheres and implications for therapy. Thesis PhD (2010); Griffith University; Brisbane; Australia PubMed=19593635; DOI=10.1007/s10549-009-0460-8 Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F., Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J., Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M., Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M., Dinjens W.N.M., Ethier S.P., Clevers H.C., Jochemsen A.G., den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M. Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines. Breast Cancer Res. Treat. 121:53-64(2010) PubMed=20070913; DOI=10.1186/1471-2407-10-15; PMCID=PMC2836299 Tsuji K., Kawauchi S., Saito S., Furuya T., Ikemoto K., Nakao M., Yamamoto S., Oka M., Hirano T., Sasaki K. Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues. BMC Cancer 10:15.1-15.10(2010) PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113 Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R. Signatures of mutation and selection in the cancer genome. Nature 463:893-898(2010) PubMed=21778573; DOI=10.3233/BD-2010-0307; PMCID=PMC3532890 Chavez K.J., Garimella S.V., Lipkowitz S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis. 32:35-48(2010) DOI=10.4172/2157-7145.S2-005 Fang R.-X., Shewale J.G., Nguyen V.T., Cardoso H., Swerdel M.R., Hart R.P., Furtado M.R. STR profiling of human cell lines: challenges and possible solutions to the growing problem. J. Forensic Res. 2 Suppl. 2:5-5(2011) PubMed=21378333 Ford C.H.J., Al-Bader M., Al-Ayadhi B., Francis I. Reassessment of estrogen receptor expression in human breast cancer cell lines. Anticancer Res. 31:521-527(2011) PubMed=22068913; DOI=10.1073/pnas.1111840108; PMCID=PMC3219108 Gillet J.-P., Calcagno A.M., Varma S., Marino M., Green L.J., Vora M.I., Patel C., Orina J.N., Eliseeva T.A., Singal V., Padmanabhan R., Davidson B., Ganapathi R., Sood A.K., Rueda B.R., Ambudkar S.V., Gottesman M.M. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc. Natl. Acad. Sci. U.S.A. 108:18708-18713(2011) PubMed=22336246; DOI=10.1016/j.bmc.2012.01.017 Kong D.-X., Yamori T. JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs. Bioorg. Med. Chem. 20:1947-1951(2012) PubMed=22347499; DOI=10.1371/journal.pone.0031628; PMCID=PMC3276511 Ruan X.-Y., Kocher J.-P.A., Pommier Y., Liu H.-F., Reinhold W.C. Mass homozygotes accumulation in the NCI-60 cancer cell lines as compared to HapMap trios, and relation to fragile site location. PLoS ONE 7:E31628-E31628(2012) PubMed=22384151; DOI=10.1371/journal.pone.0032096; PMCID=PMC3285665 Lee J.-S., Kim Y.K., Kim H.J., Hajar S., Tan Y.L., Kang N.-Y., Ng S.H., Yoon C.N., Chang Y.-T. Identification of cancer cell-line origins using fluorescence image-based phenomic screening. PLoS ONE 7:E32096-E32096(2012) PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027 Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603-607(2012) PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224; PMCID=PMC5057396 Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K., Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.-Y., van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J., Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P., Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L., Rottapel R., Neel B.G., Moffat J. Essential gene profiles in breast, pancreatic, and ovarian cancer cells. Cancer Discov. 2:172-189(2012) PubMed=22628656; DOI=10.1126/science.1218595; PMCID=PMC3526189 Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336:1040-1044(2012) PubMed=23151021; DOI=10.1186/1471-2164-13-619; PMCID=PMC3546428 Grigoriadis A., Mackay A., Noel E., Wu P.-J., Natrajan R., Frankum J., Reis-Filho J.S., Tutt A. Molecular characterisation of cell line models for triple-negative breast cancers. BMC Genomics 13:619.1-619.14(2012) PubMed=23601657; DOI=10.1186/bcr3415; PMCID=PMC3672661 Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.-J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A., Martens J.W.M. miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Res. 15:R33.1-R33.17(2013) PubMed=23856246; DOI=10.1158/0008-5472.CAN-12-3342; PMCID=PMC4893961 Abaan O.D., Polley E.C., Davis S.R., Zhu Y.-L.J., Bilke S., Walker R.L., Pineda M.A., Gindin Y., Jiang Y., Reinhold W.C., Holbeck S.L., Simon R.M., Doroshow J.H., Pommier Y., Meltzer P.S. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res. 73:4372-4382(2013) PubMed=23933261; DOI=10.1016/j.celrep.2013.07.018 Moghaddas Gholami A., Hahne H., Wu Z.-X., Auer F.J., Meng C., Wilhelm M., Kuster B. Global proteome analysis of the NCI-60 cell line panel. Cell Rep. 4:609-620(2013) PubMed=24009699; DOI=10.1371/journal.pone.0072704; PMCID=PMC3751845 Liu X., Nie H., Zhang Y.-B., Yao Y.-F., Maitikabili A., Qu Y.-P., Shi S.-L., Chen C.-Y., Li Y. Cell surface-specific N-glycan profiling in breast cancer. PLoS ONE 8:E72704-E72704(2013) PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020; PMCID=PMC3931310 Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A., Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K., McCormick F., Gray J.W. Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell 24:450-465(2013) PubMed=24162158; DOI=10.1007/s10549-013-2743-3; PMCID=PMC3832776 Prat A., Karginova O., Parker J.S., Fan C., He X.-P., Bixby L.M., Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M. Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes. Breast Cancer Res. Treat. 142:237-255(2013) PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110; PMCID=PMC3937590 Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C.B., Sukumar S., Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J., Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W. Modeling precision treatment of breast cancer. Genome Biol. 14:R110.1-R110.14(2013) PubMed=24279929; DOI=10.1186/2049-3002-1-20; PMCID=PMC4178206 Dolfi S.C., Chan L.L.-Y., Qiu J., Tedeschi P.M., Bertino J.R., Hirshfield K.M., Oltvai Z.N., Vazquez A. The metabolic demands of cancer cells are coupled to their size and protein synthesis rates. Cancer Metab. 1:20.1-20.13(2013) PubMed=24389870; DOI=10.1038/srep03576; PMCID=PMC3880960 Strauch M., Ludke A., Munch D., Laudes T., Galizia C.G., Martinelli E., Lavra L., Paolesse R., Ulivieri A., Catini A., Capuano R., Di Natale C. More than apples and oranges -- detecting cancer with a fruit fly's antenna. Sci. Rep. 4:3576-3576(2014) PubMed=24670534; DOI=10.1371/journal.pone.0092047; PMCID=PMC3966786 Varma S., Pommier Y., Sunshine M., Weinstein J.N., Reinhold W.C. High resolution copy number variation data in the NCI-60 cancer cell lines from whole genome microarrays accessible through CellMiner. PLoS ONE 9:E92047-E92047(2014) PubMed=25960936; DOI=10.4161/21624011.2014.954893; PMCID=PMC4355981 Boegel S., Lower M., Bukur T., Sahin U., Castle J.C. A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines. OncoImmunology 3:e954893.1-e954893.12(2014) PubMed=25485619; DOI=10.1038/nbt.3080 Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M. A comprehensive transcriptional portrait of human cancer cell lines. Nat. Biotechnol. 33:306-312(2015) PubMed=25877200; DOI=10.1038/nature14397 Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M. A resource for cell line authentication, annotation and quality control. Nature 520:307-311(2015) PubMed=25892236; DOI=10.1016/j.celrep.2015.03.050; PMCID=PMC4425736 Lawrence R.T., Perez E.M., Hernandez D., Miller C.P., Haas K.M., Irie H.Y., Lee S.-I., Blau C.A., Villen J. The proteomic landscape of triple-negative breast cancer. Cell Rep. 11:630-644(2015) PubMed=26055192; DOI=10.1021/acs.jproteome.5b00375 Cifani P., Kirik U., Waldemarson S., James P. Molecular portrait of breast-cancer-derived cell lines reveals poor similarity with tumors. J. Proteome Res. 14:2819-2827(2015) PubMed=26218769; DOI=10.1016/j.jchromb.2015.07.021 Willmann L., Schlimpert M., Halbach S., Erbes T., Stickeler E., Kammerer B. Metabolic profiling of breast cancer: differences in central metabolism between subtypes of breast cancer cell lines. J. Chromatogr. B 1000:95-104(2015) PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878 Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P., Loewer M., Sahin U., Castle J.C. TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression. Genome Med. 7:118.1-118.7(2015) PubMed=26649326; DOI=10.1016/j.dib.2015.09.039; PMCID=PMC4644255 Cox T.R., Schoof E.M., Gartland A., Erler J.T., Linding R. Dataset for the proteomic inventory and quantitative analysis of the breast cancer hypoxic secretome associated with osteotropism. Data Brief 5:621-625(2015) PubMed=27331101; DOI=10.1016/j.dib.2016.05.040; PMCID=PMC4905937 Aumsuwan P., Khan S.I., Khan I.A., Walker L.A., Dasmahapatra A.K. Gene expression profiling and pathway analysis data in MCF-7 and MDA-MB-231 human breast cancer cell lines treated with dioscin. Data Brief 8:272-279(2016) PubMed=27377824; DOI=10.1038/sdata.2016.52; PMCID=PMC4932877 Mestdagh P., Lefever S., Volders P.-J., Derveaux S., Hellemans J., Vandesompele J. Long non-coding RNA expression profiling in the NCI60 cancer cell line panel using high-throughput RT-qPCR. Sci. Data 3:160052-160052(2016) PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469 Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X., Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J. A landscape of pharmacogenomic interactions in cancer. Cell 166:740-754(2016) PubMed=27807467; DOI=10.1186/s13100-016-0078-4; PMCID=PMC5087121 Zampella J.G., Rodic N., Yang W.R., Huang C.R.L., Welch J., Gnanakkan V.P., Cornish T.C., Boeke J.D., Burns K.H. A map of mobile DNA insertions in the NCI-60 human cancer cell panel. Mob. DNA 7:20.1-20.11(2016) PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005; PMCID=PMC5501076 Li J., Zhao W., Akbani R., Liu W.-B., Ju Z.-L., Ling S.-Y., Vellano C.P., Roebuck P., Yu Q.-H., Eterovic A.K., Byers L.A., Davies M.A., Deng W.-L., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y.-L., Mills G.B., Liang H. Characterization of human cancer cell lines by reverse-phase protein arrays. Cancer Cell 31:225-239(2017) PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470; PMCID=PMC5557415 Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C. Glycoproteins in claudin-low breast cancer cell lines have a unique expression profile. J. Proteome Res. 16:1391-1400(2017) PubMed=28889351; DOI=10.1007/s10549-017-4496-x Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L., Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E., Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J., Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E., Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F., Lakhani S.R. Multidimensional phenotyping of breast cancer cell lines to guide preclinical research. Breast Cancer Res. Treat. 167:289-301(2018) PubMed=29273624; DOI=10.1101/gr.226019.117; PMCID=PMC5793780 Franco H.L., Nagari A., Malladi V.S., Li W.-Q., Xi Y.-X., Richardson D., Allton K.L., Tanaka K., Li J., Murakami S., Keyomarsi K., Bedford M.T., Shi X.-B., Li W., Barton M.C., Dent S.Y.R., Kraus W.L. Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis. Genome Res. 28:159-170(2018) PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675 Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A. An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines. Cancer Res. 79:1263-1273(2019) PubMed=30971826; DOI=10.1038/s41586-019-1103-9 Behan F.M., Iorio F., Picco G., Goncalves E., Beaver C.M., Migliardi G., Santos R., Rao Y., Sassi F., Pinnelli M., Ansari R., Harper S., Jackson D.A., McRae R., Pooley R., Wilkinson P., van der Meer D.J., Dow D., Buser-Doepner C.A., Bertotti A., Trusolino L., Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J. Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens. Nature 568:511-516(2019) PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103 Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569:503-508(2019) PubMed=31092827; DOI=10.1038/s41467-019-10148-6; PMCID=PMC6520398 Liu K., Newbury P.A., Glicksberg B.S., Zeng W.Z.-D., Paithankar S., Andrechek E.R., Chen B. Evaluating cell lines as models for metastatic breast cancer through integrative analysis of genomic data. Nat. Commun. 10:2138.1-2138.12(2019) PubMed=31978347; DOI=10.1016/j.cell.2019.12.023; PMCID=PMC7339254 Nusinow D.P., Szpyt J., Ghandi M., Rose C.M., McDonald E.R. 3rd, Kalocsay M., Jane-Valbuena J., Gelfand E.T., Schweppe D.K., Jedrychowski M.P., Golji J., Porter D.A., Rejtar T., Wang Y.K., Kryukov G.V., Stegmeier F., Erickson B.K., Garraway L.A., Sellers W.R., Gygi S.P. Quantitative proteomics of the Cancer Cell Line Encyclopedia. Cell 180:387-402.e16(2020) PubMed=32782317; DOI=10.1038/s41598-020-70393-4; PMCID=PMC7419295 Risha Y., Minic Z., Ghobadloo S.M., Berezovski M.V. The proteomic analysis of breast cell line exosomes reveals disease patterns and potential biomarkers. Sci. Rep. 10:13572-13572(2020) PubMed=34238275; DOI=10.1186/s12885-021-08511-2; PMCID=PMC8268371 Samson J., Derlipanska M., Zaheed O., Dean K. Molecular and cellular characterization of two patient-derived ductal carcinoma in situ (DCIS) cell lines, ETCC-006 and ETCC-010. BMC Cancer 21:790.1-790.20(2021) PubMed=34320349; DOI=10.1016/j.celrep.2021.109441; PMCID=PMC8333195 Jochems F., Thijssen B., De Conti G., Jansen R., Pogacar Z., Groot K., Wang L.-Q., Schepers A., Wang C., Jin H.-J., Beijersbergen R.L., Leite de Oliveira R., Wessels L.F.A., Bernards R. The cancer SENESCopedia: a delineation of cancer cell senescence. Cell Rep. 36:109441.1-109441.22(2021) PubMed=35042871; DOI=10.1038/s41523-021-00379-6; PMCID=PMC8766434 Rypens C., Bertucci F., Finetti P., Robertson F.M., Fernandez S.V., Ueno N.T., Woodward W.A., Van Golen K., Vermeulen P., Dirix L., Viens P., Birnbaum D., Devi G.R., Cristofanilli M., Van Laere S. Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC. NPJ Breast Cancer 8:12.1-12.12(2022) PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775 Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N., Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J., Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L., Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S., Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B., Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R. Pan-cancer proteomic map of 949 human cell lines. Cancer Cell 40:835-849.e8(2022) |